Antibiotic-resistant bacteria

Worldwide Point of Care Diagnostics Industry to 2028 - Rising Preference Towards Home Healthcare Presents Opportunities

Retrieved on: 
Thursday, March 4, 2021
Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Health care, Infection, Articles, Medical specialties

Global Point of Care (PoC) Diagnostics Market, by Infectious Diseases, by Region, 2016-2028 (USD Million)

Key Points: 
  • Global Point of Care (PoC) Diagnostics Market, by Infectious Diseases, by Region, 2016-2028 (USD Million)
    5.7.2.1.
  • Global Point of Care (PoC) Diagnostics Market, by Clostridium Difficile, by Region, 2016-2028 (USD Million)
    5.7.4.1.
  • Global Point of Care (PoC) Diagnostics Market, by Primary Care Systems, by Region, 2016-2028 (USD Million)
    5.7.9.1.
  • Global Point of Care (PoC) Diagnostics Market, by Assisted Living Healthcare Facilities, by Region, 2016-2028 (USD Million)
    8.7.1.

Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin

Retrieved on: 
Tuesday, December 22, 2020
Medical specialties, Branches of biology, Gram-negative bacteria, Pseudomonadales, Clinical medicine, Cyclic peptides, Antibiotic-resistant bacteria, Pseudomonas aeruginosa, Murepavadin, Cystic fibrosis, Pseudomonas, Nebulizer

The Phase I study is part of the clinical development plan exploring the inhaled formulation of murepavadin to treat Pseudomonas aeruginosa infections in people with cystic fibrosis, including resistant bacterial strains.

Key Points: 
  • The Phase I study is part of the clinical development plan exploring the inhaled formulation of murepavadin to treat Pseudomonas aeruginosa infections in people with cystic fibrosis, including resistant bacterial strains.
  • The safety, tolerability, and pharmacokinetic study is using eFlow Technology nebulizer (PARI Pharma GmbH) to administer murepavadin Inhalation Solution (MIS) in healthy volunteers.
  • Polyphors inhaled murepavadin is currently being developed as a precision antibiotic specifically for the treatment of chronic Pseudomonas aeruginosa infections in people with CF.
  • Based on the data of the inhaled murepavadin preclinical program suggesting significantly higher safety margins (at least 5-10 times) versus the intravenous formulation, Polyphor is initiating a clinical development program in CF.

Nozin Can Help Mitigate Growing Risk of Hospital Bacterial Infections During COVID-19, Expert Suggests

Retrieved on: 
Thursday, December 3, 2020
Articles, Health, Infectious diseases, Healthcare-associated infections, Bacterial diseases, Antibiotic-resistant bacteria, Methicillin-resistant Staphylococcus aureus, Pathovars, Staphylococcaceae, Decolonization, Mitigation, Pandemic

Published in Becker's Hospital Review, the paper demonstrates how MRSA colonization risk mitigation programs using Nozin Nasal Sanitizer antiseptic can be an effective response to pandemic-driven consequence of growing HAI risk.

Key Points: 
  • Published in Becker's Hospital Review, the paper demonstrates how MRSA colonization risk mitigation programs using Nozin Nasal Sanitizer antiseptic can be an effective response to pandemic-driven consequence of growing HAI risk.
  • The white paper, " Increased Risk of HAIs and the Case for Patient Decolonization in the COVID-19 Era , " discusses the success of Active Source ControlSM strategies to reduce colonization risk.
  • Nozin introduced NOVA programs to help successfully develop and implement MRSA colonization risk mitigation, reducing the burden on staff.
  • Note: Nozin, Nasal Sanitizer and NOVASM are registered trademarks of Global Life Technologies Corp. Nozin Nasal Sanitizer antiseptic is an OTC topical drug.

CF Foundation Awards Up to $3.3M to Polyphor for Inhaled Version of Antibiotic to Treat Pseudomonas

Retrieved on: 
Tuesday, November 24, 2020
Other Health, Research, General Health, Pharmaceutical, Philanthropy, Genetics, Foundation, Clinical trials, Science, Biotechnology, Other Science, Health, Bacteria, Medical specialties, Branches of biology, Gram-negative bacteria, Pseudomonadales, Antibiotic-resistant bacteria, Bacterial diseases, Cyclic peptides, Cystic fibrosis, Pseudomonas aeruginosa, Pseudomonas infection, Murepavadin

Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis.

Key Points: 
  • Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis.
  • An inhaled version could make it easier for someone with a Pseudomonas infection to take the drug from home.
  • In addition, the drug, which targets the outer membrane of bacteria, specifically focuses on Pseudomonas, which might have certain advantages over broad-spectrum antibiotics.
  • The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support.

DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020

Retrieved on: 
Thursday, November 12, 2020
Medical specialties, Clostridiaceae, Gram-positive bacteria, Microbiology, Infectious diseases, Antibiotic-resistant bacteria, Clostridioides difficile, CDI, Clostridioides, COVID-19 pandemic

Patients enrollment is ongoing in this Phase II trial despite a disrupted context due to the COVID-19 outbreak.

Key Points: 
  • Patients enrollment is ongoing in this Phase II trial despite a disrupted context due to the COVID-19 outbreak.
  • 40% of patients suffering a Clostridioides difficile infection (CDI) have severe forms, associated with high morbidity and mortality rates.
  • DEINOVE is a French biotech company, a pioneer in the exploitation of the unknown or little-known part of biodiversity.
  • DEINOVE, located in the Euromdecine science park in Montpellier, employs 56 people, mainly researchers, engineers and technicians, and has filed over 350 patent applications internationally.

Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol

Retrieved on: 
Monday, November 9, 2020
Bacteria, Medical specialties, Microbiology, Clostridiaceae, Gram-positive bacteria, Antibiotic-resistant bacteria, Clostridioides difficile, Clostridium difficile, Clostridium, Steatohepatitis, Microbiome

The research will also focus on development of a standalone microbiome-based treatment for non alcoholic steatohepatitis (NASH) and fibrosis.

Key Points: 
  • The research will also focus on development of a standalone microbiome-based treatment for non alcoholic steatohepatitis (NASH) and fibrosis.
  • MyBiotics' microbiome therapeutic technology enables the design of bespoke microbial consortia profiles based on MyBiotics' unique culturing and fermentation capabilities.
  • MyBiotics' lead product candidate for treatment of recurring clostridium difficile infection (CDI), MBX-SD-202, is expected to enter Phase I clinical trials in 2021.
  • "The collaboration, which aims to elevate the response rate of Aramchol, is part of our overall plan to maximize Aramchol clinical efficacy.

Pseudomonas Aeruginosa Pneumonia Pipeline Review, H2 2020 - Therapeutic Assessment of 4 Companies & 7 Drug Profiles - ResearchAndMarkets.com

Retrieved on: 
Monday, November 2, 2020
Infectious diseases, Pharmaceutical, Health, Gram-negative bacteria, Pseudomonadales, Antibiotic-resistant bacteria, Pseudomonas aeruginosa, Pseudomonas

The "Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide also reviews key players involved in therapeutic development for Pseudomonas aeruginosa Pneumonia and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Finch Therapeutics Presents Data from Its Positive PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Microbiology, Medical specialties, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Branches of biology, CP101, Finch Therapeutics

The data presented expand on the positive topline results previously reported from PRISM3, a randomized, placebo-controlled, multi-center, Phase 2 trial, which demonstrated that CP101 met the primary efficacy endpoint with a statistically significant improvement in the prevention of recurrent CDI compared to placebo.

Key Points: 
  • The data presented expand on the positive topline results previously reported from PRISM3, a randomized, placebo-controlled, multi-center, Phase 2 trial, which demonstrated that CP101 met the primary efficacy endpoint with a statistically significant improvement in the prevention of recurrent CDI compared to placebo.
  • CP101 is an investigational, orally administered microbiome drug that Finch is developing for conditions linked to microbiome dysfunction.
  • CP101 is in late-stage clinical development for the prevention of recurrent C. difficile infection.
  • Finchs Human-First Discovery platform enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms.

Venatorx Pharmaceuticals to Present Data on Cefepime-Taniborbactam at IDWeek 2020

Retrieved on: 
Wednesday, October 21, 2020
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious diseases, Clinical trials, Bacteria, Gram-negative bacteria, Chemical compounds, Organic compounds, Enterobacteriaceae, Beta-lactam antibiotics, Beta-lactamase, Antibiotic-resistant bacteria, Carbapenem, Thiazoles, Pseudomonas aeruginosa, Cefepime, Cefepime-Taniborbactam, Venatorx Pharmaceuticals, Inc.

When combined with cefepime, a fourth generation cephalosporin antibiotic, taniborbactam drives antimicrobial activity against gram-negative bacteria including carbapenemase-producing-Enterobacterales and Pseudomonas aeruginosa including multi-drug resistance strains.

Key Points: 
  • When combined with cefepime, a fourth generation cephalosporin antibiotic, taniborbactam drives antimicrobial activity against gram-negative bacteria including carbapenemase-producing-Enterobacterales and Pseudomonas aeruginosa including multi-drug resistance strains.
  • This includes pathogens that produce extended-spectrum beta-lactamases, AmpC beta-lactamases, AmpC, KPC, OXA, NDM, and VIM.
  • Venatorx is currently enrolling a Phase 3 clinical trial ( ClinicalTrials.gov NCT03840148 ) of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs).
  • Venatorx Pharmaceuticals is a private pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections.

Research Study Finds Doctor's Biome Colon Health™ Completely Inhibits the Life-Threatening C. diff.

Retrieved on: 
Wednesday, September 9, 2020
Medical specialties, Microbiology, Clostridiaceae, Gram-positive bacteria, Branches of biology, Bacteriology, Antibiotic-resistant bacteria, Clostridioides difficile, Digestive system, Probiotic, Clostridium difficile, Clostridium

"This is an exciting finding which will be the basis of our upcoming clinical trial to show the safety and efficacy of Doctor's Biome Colon Health against Clostridium difficile Infection (CDI).

Key Points: 
  • "This is an exciting finding which will be the basis of our upcoming clinical trial to show the safety and efficacy of Doctor's Biome Colon Health against Clostridium difficile Infection (CDI).
  • "Said Dr. Howard F. Robins, Founder and Chief Medical Officer of Doctor's Biome.
  • What makes Doctor's Biome Colon Health (DBCH) different from other probiotics?
  • Every batch ofDoctor's Biome Colon Healthis tested by an independent, FDA-registered accredited microbiology lab for safety (absence of pathogens).